Blog
RSS FeedPosted by Michael Wonder on 16 Jan 2023
SMC - January 2023 decisions
16 January 2023 - The Scottish Medicines Consortium, which advises on newly-licensed medicines for use by NHSScotland, has today published ...
Posted by Michael Wonder on 16 Jan 2023
Angiotensin II acetate for the treatment of patients with vasosuppressor-resistant hypotension caused by septic or distributive shock
16 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 13 Jan 2023
Public Summary Documents – September 2022 PBAC meeting
13 January 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the September 2022 PBAC ...
Posted by Michael Wonder on 11 Jan 2023
Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with advanced, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 07 Jan 2023
Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service
5 January 2023 - The main objective of this study was to explore the extent to which the incremental cost effectiveness ...
Posted by Michael Wonder on 04 Jan 2023
Mobocertinib succinate for patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer after platinum-based chemotherapy
4 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 04 Jan 2023
Updated agenda for the March 2023 PBAC meeting
4 January 2023 - The agenda for the March 2023 PBAC meeting has been updated. ...
Posted by Michael Wonder on 03 Jan 2023
Pertuzumab and pertuzumab with trastuzumab in breast cancer: now a minor additional clinical benefit
2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of ...
Posted by Michael Wonder on 22 Dec 2022
ICER releases draft evidence report on treatments for Alzheimer’s disease
22 December 2022 - Registration now open for 5 January “Early Insights” webinar. ...
Posted by Michael Wonder on 22 Dec 2022
NICE recommends a weekly injection for treating growth failure in children
22 December 2022 - This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments. ...
Posted by Michael Wonder on 22 Dec 2022
ICER publishes final evidence report on gene therapies for haemophilia A and B
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
Posted by Michael Wonder on 21 Dec 2022
ICER publishes evidence report on treatments for multiple sclerosis
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
Posted by Michael Wonder on 20 Dec 2022
ICER provides update on value based pricing of Paxlovid as an outpatient treatment for COVID-19
20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment ...
Posted by Michael Wonder on 20 Dec 2022
Meta-analyses with very few studies: different beta-binomial models in comparison
16 December 2022 - A team led by IQWiG authors compared the usual beta-binomial model for meta-analysis of small study pools ...
Posted by Michael Wonder on 20 Dec 2022
NICE recommends Enhertu for more people with advanced breast cancer
20 December 2022 - Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage ...